Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone's In-Licensed Cancer Treatment Meets Endpoints in Phase III Trial

publication date: May 23, 2019

Suzhou's CStone Pharma announced its in-licensed product, Tibsovo (ivosidenib), produced a substantial improvement in progression-free survival in previously treated patients with cholangiocarcinoma. The results came from a US Phase III trial of Tibsovo conducted by Agios, a Boston area pharma and CStone's partner. In June 2018, CStone acquired greater China rights to Tibsovo from Agios in a deal worth up to $424 million. Tibsovo is already approved in the US to treat acute myeloid leukemia (AML). More details....

Stock Symbols: (HK: 2616) (NSDQ: AGIO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.